Finanzen von Gossamer Bio Inc (GOSS)GOSSGossamer Bio Inc

Evaluating the bottom line, Gossamer Bio, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -282.25%, while the net margin is 182.94%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively GOSS converts its operational activities into shareholder value.

In the context of the broader market, GOSS competes directly with industry leaders such as ACET and TENX. With a market capitalization of $75.38M, it holds a significant position in the sector. When comparing efficiency, GOSS's gross margin of 100.00% stands against ACET's N/A and TENX's N/A. Such benchmarking helps identify whether Gossamer Bio, Inc. is trading at a premium or discount relative to its financial performance.

Gossamer Bio reported a net income of $16,900,000 in Q2 2026, a significant turnaround from previous losses. However, the company has a negative EPS of -0.20 and a forward P/E of 0, indicating uncertainty in profitability.